Finlay Vaccine - Product Scorecard

Company: Finlay Institute

Type: Covid-19 Vaccine
Product (brand name): Finlay-FR-1 (Soberana 02, Pasteurcovac)
0%
compliance
with criteria
Share this score on social:

Other company scores

Bharat Biotech Vaccine
0%
Brii BioSciences Therapeutic
0%
CanSino Vaccine
0%
Celltrion Therapeutic
0%
CIGB Vaccine
0%
Texas Children’s Hospital Vaccine
0%
Finlay Vaccine
0%
Gamaleya Vaccine
0%
Gilead Therapeutic
0%
Johnson & Johnson Vaccine
0%
Moderna Vaccine
0%
Vaxine Vaccine
0%
Vektor Vaccine
0%
Zydus Vaccine
0%
AstraZeneca Antibody
0%
AstraZeneca Vaccine
0%
Eli Lilly Therapeutic 3
0%
Eli Lilly Therapeutic 2
0%
Eli Lilly Therapeutic 1
0%
MSD Therapeutic
0%
Novavax Vaccine
0%
Pfizer Therapeutic
0%
Pfizer Vaccine
0%
Regeneron Therapeutic
0%
Roche Therapeutic
0%
Sanofi Vaccine
0%
Sinopharm Vaccine
0%
Sinovac Vaccine
0%
GSK Therapeutic
0%
Explore the results of PAF’s research into the behaviour of Finlay Institute. Each section is given an overall score; individual criteria are also scored (see icon following the criteria heading).

Click on ‘Explanation about the score’ sign next to each entry to expand and learn more.

Category A: Commitments and Accountability

The company should publicly commit to human rights in relation to product development and marketing, by adopting an official human rights policy statement recognising the right to the highest attainable standard of health. The company should endeavour to integrate human rights into its strategies, policies, programmes, projects, and activities.

The company should also have a publicly available global access plan for their Covid-19 product, based on human rights standards, with measurable targets and lines of accountability.

A1: Does Finlay Institute publish a global access plan for its product?

Finlay has agreed to collaborate on vaccine trials and to open licensing for other countries to produce Soberana 02. Venezuela has taken up the offer. Its open licensing, open patents approach will contribute to global access to the vaccine. 

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
A2: Does Finlay Institute commit to comply with human rights standards in relation to product development and marketing?

The ‘our values’ section on Finlay’s website refers to ‘good practices for the production of vaccines with a business, social and environmental security approach’. There is no mention of human rights.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody

Category C: International cooperation

The company should constructively engage with international initiatives for the equitable distribution of vaccines and therapeutics, such as the Covid-19 Technology Access Pool (C-TAP) or the Medicines Patent Pool (MPP), and the ACT Accelerator (COVAX). The company should also publicly commit to not enforcing the exclusive rights of Covid-19 related patents, and enter into non-exclusive, transparent licensing agreements for its Covid-19 products with other companies.

C1: Does Finlay Institute commit to C-TAP or MPP?

At the Summit for Vaccine Internationalism (led by the Global South) Cuba committed to open licensing technology for Soberana 2 (including patents & know-how). KEI encouraged Cuba to collaborate with C-TAP. Hopefully Finlay will commit to one of these licensing mechanisms once Soberana 02 receives WHO regulatory approval.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
C2: Does Finlay Institute commit to not enforcing the exclusive rights of Covid-19 related patents?

Cuba’s biotech sector is public and it has declared itself to be favourable to the general waiving of monopolies for Covid-19 products. Its patents are therefore public and ‘free to facilitate tech transfer’. Soberana 02 is known as an ‘open-source vaccine’ and the effect of this is equivalent to the company not enforcing its exclusive patent rights.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
C3: Does Finlay Institute supply to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator?

Cuba is currently ‘assessing the possibility of Cuban participation’ in Covax and is in talks with the Coalition for Epidemic Preparedness Initiative (CEPI).

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
C4: Does Finlay Institute agree to license its Covid-19 medical products to other companies?

Finlay has made offers of open licensing, and stated that they would be ‘open to licensing the intellectual property around the vaccines with a small profit margin’. Iran is already producing the vaccine, and Vietnam, Argentina and Mexico have stated that they hope to produce the Cuban vaccines soon.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody

Category E: Equality, non-discrimination & equity

The company should engage in efforts to further equitable distribution of Covid-19 vaccines/therapeutics, by equitably distributing its supplies globally, devising fair pricing strategies, and making the active ingredient for its product available to other manufacturers. The company should also engage in full technology transfer to other manufacturers, including the necessary transfer of skills, legal components, knowledge and intellectual property. Where applicable, the company should agree to waive rights in regulatory test data, and refrain from enforcing TRIPS+ measures.

E1: Does Finlay Institute make the active ingredient available on reasonable grounds? [Only for therapeutics]

[Only applies to therapeutics]

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
E2: Does Finlay Institute commit to full technology transfer to other manufacturers?

Finlay has committed to full technology transfer to the Iranian Pasteur Institute for production of Soberana 2 (Jan 08, 2021). It has also signed a letter of Intent with Argentina to collaborate on vaccine R&D; technology transfer, including active materials needed to make the vaccine, to Ghana.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
E3: Does Finlay Institute commit to non-profit, ‘fair’, or differential pricing?

Cuba’s Vice Minister for Health said the vaccines will be ‘affordable and will benefit those most in need’, and has suggested that it will adopt a tiered pricing approach, offering the vaccines free or at cost to poorer nations, and charging more to developed countries. The vaccine is non-profit domestically

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine